NVO Novo Nordisk Earnings and EPS analysis

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 96

EPS in 2026 (TTM): 26.23 DKK

Last Report Period Date: Jun 30, 2026

Currently, NVO's 12-month EPS stands at 26.23 DKK, according to the most recent financial reports. Novo Nordisk's earnings per share in 2025 was reported at 23.06 DKK, marking a rise from 22.67 DKK in 2024. NVO recorded an EPS of 4.74 DKK for the quarterly period ending on Jun 30, 2026.

NVO earnings history

Historical annual and quarterly earnings per share (EPS) data for Novo Nordisk
EPS (TTM)
26.23 DKK
EPS Growth YoY (Quarterly)
-20.5%
EPS (Quarterly)
4.74 DKK
EPS Growth (Quarterly)
-56.6%

In 2025, Novo Nordisk's earnings per share was 23.06 DKK, a rise of 1.7% from 22.67 DKK in 2024. The quarterly earnings per share for the period ending Jun 30, 2026, was 4.74 DKK, showing a 20.5% decline compared to the same quarter last year. The trailing twelve months EPS for NVO is 26.23 DKK as of June 2026. Novo Nordisk's full-year EPS for 2024 was 22.67 DKK, a 21.4% rise compared to the previous year.

NVO EPS vs price chart

NVO EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
-20.5%
EPS growth YoY
1.7%
EPS growth 3Y avg
23.4%
EPS growth 5Y avg
20.7%

Novo Nordisk has recorded a decline in earnings per share of 20.5% in the past 12 months (YoY, quarterly). Across the past three years, the company had an average EPS annual growth rate of 23.4% per year. Novo Nordisk had an average annual EPS growth of 20.7% in the last five years. When assessed over a ten-year period, NVO's average EPS annual growth was 13%.

NVO Earnings Waterfall

Breakdown of revenue, profit and net income for Novo Nordisk

NVO Earnings vs Peers

What are the earnings of NVO compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
NVO Novo Nordisk 11.46 1.7% 23.4% 20.7%
BMY Bristol-Myers Squibb Company 14.03 178.7% 5.3% N/A
REGN Regeneron Pharmaceuticals Inc 19.16 5.3% 2.1% 5.7%
NVS Novartis AG 22.65 21.8% 31.2% 15.2%
AZN Astrazeneca plc 23.21 45.4% 46% 22%
AMGN AMGEN Inc 25.6 88.1% 5.6% 2.9%
LLY Lilly(Eli) & Company 39.55 95.6% 49.2% 27.5%
MRK Merck & Co Inc 106.96 8% 8.4% 21.2%
GILD Gilead Sciences Inc N/A 1,700% 23.2% 132.8%

All data is based on quarterly TTM periods, unless otherwise specified.